Last $3.99 USD
Change Today -0.01 / -0.25%
Volume 773.0K
ONTX On Other Exchanges
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

onconova therapeutics inc (ONTX) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/30/14 - $16.22
52 Week Low
12/9/14 - $3.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

onconova therapeutics inc (ONTX) Related Businessweek News

No Related Businessweek News Found

onconova therapeutics inc (ONTX) Details

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. Its clinical-stage product candidates include rigosertib intravenous that is in Phase III trials for higher risk myelodysplastic syndromes (MDS); rigosertib Oral, which is Phase II clinical trials for patients with transfusion-dependent lower risk MDS and in patients with head and neck cancers; and a combination of rigosertib Oral and azacitidine in a Phase 1/2 study of first-line MDS patients. The company’s clinical-stage product candidates also comprise ON 013105, a small molecule targeting an important regulatory protein, cyclin D1, which is found at elevated levels in cancer cells; and recilisib, a molecule with radiation protection properties has completed four Phase I clinical trials. In addition, its preclinical products consist of ON 1231320, an inhibitor of polo-like kinase 2; ON 123300, an inhibitor of the cell cycle and cancer cell metabolism; ON 108600, an inhibitor of cyclin-dependent kinase 9 and casein kinase 2; ON 044580, a dual inhibitor of janus kinase 2 and Bcr-Abl kinase; ON 24 series of compounds that are oral anti-tubulin agents; and ON 146 series, which are selective inhibitors of PI3K alpha/delta isoforms. It has a development and license agreement with Baxter Healthcare SA; and a license agreement with SymBio Pharmaceuticals Limited. The company was founded in 1998 and is headquartered in Newtown, Pennsylvania.

64 Employees
Last Reported Date: 03/20/14
Founded in 1998

onconova therapeutics inc (ONTX) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $742.8K
Chief Financial Officer and Secretary
Total Annual Compensation: $347.9K
President of Research and Development
Total Annual Compensation: $359.0K
Senior Vice President of Product Development
Total Annual Compensation: $424.8K
Compensation as of Fiscal Year 2013.

onconova therapeutics inc (ONTX) Key Developments

Onconova Therapeutics, Inc. Announces Data from Clinical Trials of Rigosertib in Myelodysplastic Syndromes and Non-Proliferative Acute Myeloid Leukemia

Onconova Therapeutics, Inc. announced the presentation of data from clinical trials of rigosertib in myelodysplastic syndromes (MDS) and non-proliferative acute myeloid leukemia (AML) at the American Society of Hematology (ASH) Annual Meeting. Based on synergistic anti-leukemic activity of the combination of rigosertib and azacitidine demonstrated in non-clinical studies, an exploratory, dose-range finding study was conducted at Mount Sinai Medical Center and the MD Anderson Cancer Center. A total of 18 patients with MDS or non-proliferative AML, who were either previously untreated with hypomethylating agents (HMAs), or who had failed or progressed on an HMA, were included in this study. The indicated dose of azacitidine (75 mg/m2/day) was given in combination with escalating doses of oral rigosertib in three successive cohorts (140-560 mg given two times daily). Oral rigosertib was administered from day one through day 21 of a 28-day cycle. Azacitidine was administered for seven days starting on day eight of the 28-day cycle. Nine patients with MDS, eight patients with AML and one patient with CMML received the combination.  Responses according to International Working Group (IWG) criteria were observed. Marrow complete remission (mCR) was achieved in five patients (2 AML; 3 MDS). Complete remission with incomplete recovery of blood counts (CRi) was observed in four patients (1 AML; 3 MDS), and stable disease (SD) was observed in two patients (1 MDS; 1 CMML). Measures of hematological improvement, including increases in platelet (1 AML; 2 MDS patients), erythroid (2 MDS patients) and neutrophil (2 MDS patients) counts were observed with the combination. Notably, two MDS patients who responded had previously failed treatment with a hypomethylating agent. The most frequently reported adverse events in cycle 1 included constipation, diarrhea, nausea, fatigue, hypotension, and pneumonia. The adverse events did not differ significantly among the three dosing cohorts. The only adverse events of Grade 3 or greater that occurred in more than one patient were pneumonia (4), neutropenia, (3), febrile neutropenia (2) and thrombocytopenia (2). Elevation in creatinine in one patient in the first cohort was deemed as a possible treatment-related Grade 3 dose-limiting toxicity that required subsequent expansion of the cohort. Overall, the adverse event profile did not appear to differ significantly from that reported for azacitidine alone. The Phase 2 segment of the study is underway in multiple centers to further assess the response to the combination.

Onconova Therapeutics, Inc. - Special Call

To discuss rigosertib development for multiple MDS indications

Onconova Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Onconova Therapeutics, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, revenue was $114,000 against $1,116,000 a year ago. Loss from operations was $14,888,000 against $20,104,000 a year ago. Net loss before income taxes was $14,907,000 against $20,089,000 a year ago. Net loss was $14,907,000 against $20,521,000 a year ago. Net loss applicable to common stockholders was $14,878,000 or $0.69 per basic and diluted share against $20,790,000 or $1.34 per basic and diluted share a year ago. For the nine months, revenue was $686,000 against $2,823,000 a year ago. Loss from operations was $50,385,000 against $47,663,000 a year ago. Net loss before income taxes was $50,403,000 against $47,496,000 a year ago. Net loss was $50,403,000 against $47,928,000 a year ago. Net loss applicable to common stockholders was $50,310,000 or $2.32 per basic and diluted share against $50,248,000 or $7.23 per basic and diluted share a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONTX:US $3.99 USD -0.01

ONTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONTX.
View Industry Companies

Industry Analysis


Industry Average

Valuation ONTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 33.1x
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCONOVA THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at